SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 2160480

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 2160480

Oncolytic Virus Cancer Therapy Market Size, Share, and Growth Analysis, By Virus Type, By Therapy Type, By Cancer Type, By Route of Administration, By End-Use Industry, By Region - Industry Forecast 2026-2033

PUBLISHED:
PAGES: 157 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5300
PDF & Excel (Multiple User License)
USD 6200
PDF & Excel (Enterprise License)
USD 7100

Add to Cart

Global Oncolytic Virus Cancer Therapy Market size was valued at USD 156.8 Million in 2024 and is poised to grow from USD 185.49 Million in 2025 to USD 711.56 Million by 2033, growing at a CAGR of 18.3% during the forecast period (2026-2033).

The Global Oncolytic Virus Cancer Therapy market focuses on biologic agents designed to selectively target and destroy malignant cells while enhancing antitumor immunity. This market addresses a significant demand for alternatives to conventional chemotherapy and checkpoint inhibitors. Following pivotal regulatory approvals, the sector has gained momentum, with increased venture capital and collaborations between biotech firms and academic institutions, leading to a vibrant pipeline. The primary driver of growth is the integration of advanced genetic engineering with personalized oncology, enhancing therapeutic effectiveness. AI technologies are transforming the field by improving target discovery, vector design, and patient selection, significantly reducing development timelines and costs. This increased efficiency is attracting investment and facilitating the broader adoption of oncolytic viruses within the immuno-oncology landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncolytic Virus Cancer Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncolytic Virus Cancer Therapy Market Segments Analysis

Global oncolytic virus cancer therapy market is segmented by virus type, therapy type, cancer type, route of administration, end-use industry and region. Based on virus type, the market is segmented into Adenovirus, Herpes Simplex Virus, Vaccinia Virus, Reovirus, Newcastle Disease Virus and Others. Based on therapy type, the market is segmented into Monotherapy, Combination Therapy and Others. Based on cancer type, the market is segmented into Melanoma, Lung Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer and Others. Based on route of administration, the market is segmented into Intratumoral, Intravenous, Intraperitoneal and Others. Based on end-use industry, the market is segmented into Hospitals, Cancer Treatment Centers, Pharmaceutical Companies, Biotechnology Companies, Research Institutions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Oncolytic Virus Cancer Therapy Market

The Global Oncolytic Virus Cancer Therapy market is positively influenced by the rise of personalized immunotherapy, which utilizes tumor-specific viral vectors. This innovative strategy allows clinicians to customize treatments based on individual genetic profiles, leading to enhanced therapeutic effectiveness and fewer adverse events. As oncologists witness improved outcomes for their patients, their willingness to adopt oncolytic virus therapies as integral components of treatment protocols increases. This, in turn, boosts participation in clinical trials and broadens real-world application, stimulating pharmaceutical investments and driving ongoing innovation. As a result, the market experiences consistent growth, reflecting the integration of scientific progress with clinical implementation.

Restraints in the Global Oncolytic Virus Cancer Therapy Market

The complexity of manufacturing oncolytic virus therapies poses significant challenges that hinder scalability. These therapies necessitate stringent aseptic conditions, meticulous vector engineering, and comprehensive quality control measures. Each batch produced must ensure both viral potency and genetic stability, which requires specialized facilities and highly trained personnel. Such rigorous requirements lead to longer lead times and restrict the capacity to fulfill increasing demand, particularly for multi-dose treatments. As a result, supply chain bottlenecks occur, dissuading healthcare providers from adopting these innovative therapies, despite the clinical promise they hold, ultimately limiting market growth and the potential for swift industry expansion.

Market Trends of the Global Oncolytic Virus Cancer Therapy Market

The Global Oncolytic Virus Cancer Therapy market is witnessing a significant trend driven by the integration of oncolytic viruses with established immunotherapeutic modalities, such as checkpoint inhibitors and CAR-T cells. This synergistic approach is redefining treatment protocols as healthcare professionals strive to enhance antitumor immune responses. Successful collaborative clinical programs are yielding improved response durability and expanding patient eligibility, prompting pharmaceutical companies to pivot their research and development strategies toward combination therapies. As regulatory bodies respond to this innovative landscape, oncolytic virus platforms are being positioned as essential elements of advanced immuno-oncology suites, thereby diversifying market applications and creating new avenues for revenue for biotech firms globally.

Product Code: SQMIG35I3755

Table of Contents

Introduction

  • Objectives of the Study
  • Market Definition & Scope

Research Methodology

  • Research Process
  • Secondary & Primary Data Methods
  • Market Size Estimation Methods

Executive Summary

  • Global Market Outlook
  • Key Market Highlights
  • Segmental Overview
  • Competition Overview

Market Dynamics & Outlook

  • Macro-Economic Indicators
  • Drivers & Opportunities
  • Restraints & Challenges
  • Supply Side Trends
  • Demand Side Trends
  • Porter's Analysis & Impact
    • Competitive Rivalry
    • Threat of Substitutes
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factors
  • Market Impacting Factors
  • Top Investment Pockets
  • Ecosystem Mapping
  • Market Attractiveness Index 2025
  • PESTEL Analysis
  • Regulatory Landscape

Global Oncolytic Virus Cancer Therapy Market Size by Virus Type & CAGR (2026-2033)

  • Market Overview
  • Adenovirus
  • Herpes Simplex Virus
  • Vaccinia Virus
  • Reovirus
  • Newcastle Disease Virus
  • Others

Global Oncolytic Virus Cancer Therapy Market Size by Therapy Type & CAGR (2026-2033)

  • Market Overview
  • Monotherapy
  • Combination Therapy
  • Others

Global Oncolytic Virus Cancer Therapy Market Size by Cancer Type & CAGR (2026-2033)

  • Market Overview
  • Melanoma
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Head and Neck Cancer
  • Others

Global Oncolytic Virus Cancer Therapy Market Size by Route of Administration & CAGR (2026-2033)

  • Market Overview
  • Intratumoral
  • Intravenous
  • Intraperitoneal
  • Others

Global Oncolytic Virus Cancer Therapy Market Size by End-Use Industry & CAGR (2026-2033)

  • Market Overview
  • Hospitals
  • Cancer Treatment Centers
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Research Institutions
  • Others

Global Oncolytic Virus Cancer Therapy Market Size & CAGR (2026-2033)

  • North America (Virus Type, Therapy Type, Cancer Type, Route of Administration, End-Use Industry)
    • US
    • Canada
  • Europe (Virus Type, Therapy Type, Cancer Type, Route of Administration, End-Use Industry)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Virus Type, Therapy Type, Cancer Type, Route of Administration, End-Use Industry)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Virus Type, Therapy Type, Cancer Type, Route of Administration, End-Use Industry)
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Virus Type, Therapy Type, Cancer Type, Route of Administration, End-Use Industry)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Amgen
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Replimune
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Targovax
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • SillaJen
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takara Bio
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PsiOxus Therapeutics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CG Oncology
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Oncorus
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Transgene
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • DNAtrix
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vyriad
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Oncolytics Biotech
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genelux
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Viralytics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sarepta Therapeutics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!